arrow
J

J.L. Geiger

cleveland clinic
H指数:24
被引数:3,831

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study

皮下注射阿曼曲单抗在复发性/转移性头颈鳞状细胞癌中的应用:在免疫检查点抑制剂和化疗后疾病进展的患者中的初步结果,来自OrigAMI-4研究(1b/2期)

2025-11-220
OAAI
Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer – Results from xxxxx

自评听力结局:HPV阳性口咽癌患者接受放疗联合顺铂或放疗联合西妥昔单抗治疗的结果——来自xxxxx的研究

2025-08-180
PRE
Imaging Extranodal Extension (iENE) Predicts Higher Rates of Distant Recurrence for Human Papillomavirus-Positive Oropharyngeal Cancer

影像学显示的结外侵犯(iENE)预测人乳头瘤病毒阳性口咽癌远处复发率更高

2025-03-300
PRE
Head and Neck Cancers, Version 2.2025 Featured Updates to the NCCN Guidelines

头颈癌,版本2.2025:NCCN指南特色更新

2025-02-012
PRE
mRNA-4157 (V940) individualized neoantigen therapy (INT) plus pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): Clinical & translational analysis
2024-04-050
PRE
Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer A Single-Institution 21-Year Experience
2023-04-0113
OA
Risk Factors Associated With Recurrence and Death in Patients With Tall Cell Papillary Thyroid Cancer A Single-Institution Cohort Study With Predictive Nomogram
2023-01-019
OA
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
2022-10-27142
OA
18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002
2022-09-021
OA
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
2022-09-021
OA
Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative study
2022-03-014
PRE
Head and Neck Cancers, Version 1.2022 Featured Updates to the NCCN Guidelines

头颈癌,1.2022版更新了NCCN指南

2022-03-01255
OA
NEMVALEUKIN ALFA, A NOVEL ENGINEERED IL-2 CYTOKINE, IN COMBINATION WITH THE ANTI-PD-1 ANTIBODY PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (ION-01 STUDY)
2021-11-103
OA